BioPorto Q1-Q3 2020 Interim Report

BioPorto's interim report covering the first three quarters of 2020, detailing financial results, NGAL regulatory strategy and status, and updates on the gRAD COVID rapid test. The document includes key milestones achieved during the period and information about the company's operations.